Gentian Diagnostics ASA
Develops and markets in vitro diagnostic reagents for human and veterinary use.
GENT | OL
Overview
Corporate Details
- ISIN(s):
- NO0010748866
- LEI:
- 5967007LIEEXZXHNM861
- Country:
- Norway
- Address:
- Bjørnåsveien 5, 1596 Moss
- Website:
- https://www.gentian.com/
- Sector:
- Manufacturing
Description
Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-16 12:33 |
Financial calendar
|
English | 654 bytes | ||
| 2021-12-16 07:47 |
Completed development of SARS Cov-2 antibody assay
|
English | 2.6 KB | ||
| 2021-12-16 07:34 |
Gentian Diagnostics presents at the DNB Nordic Healthcare Conference
|
English | 725.2 KB | ||
| 2021-12-16 07:34 |
Gentian Diagnostics presents at the DNB Nordic Healthcare Conference
|
English | 750 bytes | ||
| 2021-12-10 08:42 |
Share capital increase registered - Correction*
|
English | 1.1 KB | ||
| 2021-12-09 14:02 |
Share capital increase registered
|
English | 1.1 KB | ||
| 2021-11-30 14:06 |
Mandatory notification of trade
|
English | 631.9 KB | ||
| 2021-11-30 14:06 |
Mandatory notification of trade
|
English | 2.4 KB | ||
| 2021-11-29 15:22 |
Share Issue in Connection with Employee Share Purchase Program
|
English | 1.6 KB | ||
| 2021-11-03 11:32 |
Multicenter study confirms calprotectin’s role in risk stratification in COVID-…
|
English | 1.3 MB | ||
| 2021-11-03 11:31 |
Multicenter study confirms calprotectin’s role in risk stratification in COVID-…
|
English | 3.1 KB | ||
| 2021-11-01 12:07 |
New study supports the value of calprotectin in management of COVID-19 patients
|
English | 851.8 KB | ||
| 2021-11-01 12:07 |
New study supports the value of calprotectin in management of COVID-19 patients
|
English | 2.7 KB | ||
| 2021-10-21 06:00 |
Third quarter 2021 financial report
|
English | 4.2 MB | ||
| 2021-10-21 06:00 |
Third quarter 2021 financial report
|
English | 727.2 KB |
Automate Your Workflow. Get a real-time feed of all Gentian Diagnostics ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gentian Diagnostics ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gentian Diagnostics ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
